Monte Rosa Therapeutics, Inc. GLUE

11.77 0.05 0.43% as of 25 Sep
Market cap
$999.9M
P/E
0.0×
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '17
P/E ratio
0.00 0.00 — — — — — —
P/S ratio
10.53 6.78 — — — — — —
P/FCF ratio
0.00 13.50 — — — — — —
P/Operating CF
(30.28) 3.98 — — — — — —
P/B ratio
5.59 2.30 — — — — — —
Price to Tangible BV
5.59 2.30 — — — — — —
EV/Sales
7.48 1.86 — — — — — —
EV/EBITDA
0.00 0.00 — — — — — —
EV/Operating CF
(40.59) 3.35 — — — — — —
EV/FCF
(33.66) 3.70 — — — — — —
Quick Ratio
6.05 2.37 5.00 10.62 20.80 1.42 2.15 —
Current Ratio
6.12 2.40 5.07 10.79 20.96 1.49 2.27 —
Net Debt/EBITDA
8.22 5.10 1.70 2.43 4.89 1.52 (1.23) —
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 170.81% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00 0.00 0.00 (1.56) —
Asset Turnover
0.28 0.20 0.00 0.00 0.00 0.00 0.00 —
Operating CF/Net income
0.59 (0.58) 0.32 0.85 0.80 0.64 0.80 —
Capex/Depreciation
(0.56) (0.49) (3.05) (3.42) (4.53) (6.31) 0.00 —
Interest Coverage
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
ROE
(16.94%) (36.15%) (60.07%) (35.06%) (49.51%) 117.88% 25.43% —
ROA
(8.71%) (19.58%) (41.90%) (30.62%) (35.58%) (118.66%) (139.53%) —
ROIC
0.00% 0.00% 0.00% (920.94%) (3,154.52%) 0.00% 0.00% —
Return on Tangible Assets
(10.88%) (29.08%) (60.58%) (39.11%) (21.48%) (189.45%) (113.79%) —
Average Days of Receivables
34.24 0.84 0.00 0.00 — — — —
Research and Development Expense of Revenue
114.42% 160.75% 0.00% 0.00% 0.00% 0.00% 0.00% —
Selling, General and Administrative Expense of Revenue
29.42% 46.51% 0.00% 0.00% 0.00% 0.00% 0.00% —
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
15.25% 23.97% 0.00% 0.00% 0.00% 0.00% — —
Graham Net Nets
0.14 0.32 — — — — — —
Graham Number
0.00 0.00 — — — — — —
Earnings Yield
(2.93%) (14.70%) — — — — — —
Free Cash Flow Yield
(2.11%) 7.41% — — — — — —
Revenue per Share
1.49 1.02 0.00 0.00 0.00 0.00 0.00 —
Operating CF per Share
(0.27) 0.57 (0.85) (1.96) (2.37) (15.20) (0.14) —
Capex per Share
(0.06) (0.05) (0.37) (0.27) (0.39) (2.23) 0.00 —
Free Cash Flow per Share
(0.33) 0.51 (1.22) (2.23) (2.76) (17.43) (0.14) —
Cash per Share
4.54 5.04 4.52 5.59 13.84 27.49 0.21 —
Shareholders Equity per Share
2.81 3.02 3.49 5.75 13.90 (32.12) (0.28) —
Interest Debt per Share
0.00 0.00 0.00 0.00 0.00 0.00 0.00 —
Book value per Share
2.81 3.02 3.49 5.75 13.90 (32.12) (0.28) —
Free Cash Flow
(27.50) 38.01 (62.78) (105.27) (69.02) (26.44) (6.17) —
Working Capital
328.97 220.49 189.62 250.32 332.03 14.32 5.47 —
Capital Expenditures
(4.70) (3.99) (18.98) (12.80) (9.65) (3.39) (1.38) —
Net Current Asset Value
177.58 161.64 111.71 204.91 329.85 (54.51) (13.48) —
EV/EBIT
0.00 0.00 — — — — — —
Capex to Sales
0.04 0.05 0.00 0.00 0.00 0.00 — —
Net Profit Margin
(31.23%) (96.14%) 0.00% 0.00% 0.00% 0.00% 0.00% —
Price to Operating Income
0.00 0.00 — — — — — —
Other line items
Depreciation/Fixed assets
0.32 0.28 0.18 0.14 0.17 0.12 0.05 —
Cash ROIC
(8.00%) 2.10% (18.85%) (22.34%) (10.34%) 393.74% (46.79%) —
Accounts Receivable Turnover
21.01 223.07 0.00 — — — — —
Accounts Payable Turnover
0.00 0.00 0.00 0.00 0.00 0.00 0.01 —
Inventory Turnover
— — — 0.00 0.00 0.00 0.00 —
Average Days of Payables
0.00 0.00 0.00 0.00 0.00 0.00 16,196.88 —
Days of Inventory on Hand
— — — 0.00 0.00 0.00 0.00 —
Average Receivables
5.89 0.34 4.08 — — — — —
Average Payables
10.38 14.18 9.51 7.21 6.81 5.13 5.13 —
Average Assets
443.70 371.24 323.07 354.36 207.85 30.24 5.55 —
Average Common Equity
228.00 201.09 225.33 309.46 149.39 (30.44) (30.44) —

Fold the line items

Columns are period end dates